SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
This article was originally published in The Tan Sheet
Executive Summary
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm